IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2708
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$86M
Nadav Kidron
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its flagship product is the ORMD-0801, an oral ingestible insulin capsule. It is also developing an oral glucagon-like peptide-1 capsule.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$ORMP ORAMED PHARMACEUTICALS INC. | 46 | 35 | 25 | 73 | 3.7x | - | 17.0% | 15.6% | 0.7% | -225.0% | -382.1% | -1.0% | 0.0% | 9.0x | $86M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ORAMED PHARMACEUTICALS INC. (ORMP) receives a "Reduce" rating with a composite score of 45.6/100. It ranks #2708 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Nadav Kidron
Chief Executive Officer
Labor Force
10
35
28
74
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for ORMP
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ORMP.
View All RatingsEarnings well-supported by fundamental cash flows
High margin volatility — erratic forensic earnings quality
ROE proxy 17.0% (sector -2.5%)
GM 1% vs sector 43%, OM -225% vs sector 1%
Capital turnover N/A
Rev growth -1%, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
ORAMED PHARMACEUTICALS INC. receives a Reduce rating from our analysis, with a composite score of 45.6/100 and 2 out of 5 stars, ranking #2708 out of 7,333 stocks. ORMP's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
ORMP's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 17.0% (sector avg: -2.5%), gross margins of 0.7% (sector avg: 42.5%), net margins of -382.1% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
ORMP registers a value score of just 25/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/E ratio of 3.73x, a P/B ratio of 0.63x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
ORAMED PHARMACEUTICALS INC.'s investment score of 28/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -1.0% vs. a sector average of 5.9% and a return on assets of 15.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ORMP shows strong momentum characteristics with a score of 73/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at -1.0% year-over-year, while a beta of 0.86 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
ORMP shows good financial stability with a score of 74/100. Key stability metrics include a beta of 0.86 and a debt-to-equity ratio of 9.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
ORAMED PHARMACEUTICALS INC.'s short interest score of 38/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 9.00x), micro-cap liquidity risk. At $86M (micro-cap), ORMP carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
ORAMED PHARMACEUTICALS INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2708 of 7,333 overall (63rd percentile). Key comparisons include ROE of 17.0% exceeding the -2.5% sector median and operating margins of -225.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ORMP currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (25) would have the largest impact on the composite score.
ROE 785% BELOW SECTOR MEDIAN
Gross Margin 98% BELOW SECTOR MEDIAN
Op. Margin 17542% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate ORAMED PHARMACEUTICALS INC. (ORMP) as a Reduce with a composite score of 45.6/100 at a current price of $3.45. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (74th percentile) and momentum (73th percentile), which together account for the majority of the composite score. Offsetting weakness in value (25th percentile) and investment (28th percentile) tempers our overall conviction. We assign a No Moat rating (25/100), Medium uncertainty, and Standard capital allocation.
Key items to watch: whether strong momentum is fundamentally supported by revenue trends; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ORAMED PHARMACEUTICALS INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 45.6/100 places it at rank #2708 in our full 7,333-stock universe. At $86M in market capitalization, ORAMED PHARMACEUTICALS INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Despite positive momentum (73th percentile), revenue contraction of -1% creates a divergence between price action and fundamental trajectory. This divergence suggests either that the market is looking through near-term weakness or that technical factors are temporarily inflating the stock. Investors should assess whether the revenue decline reflects cyclical weakness or structural challenges.
The margin cascade tells an important story: gross margins of 1% (-41.9pp vs sector) narrow to operating margins of -225% (-226.3pp vs sector) and net margins of -382.1%, yielding a gross-to-net conversion rate of -58785%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $3.45, ORAMED PHARMACEUTICALS INC. is trading at a premium to fundamental value. Our value factor score of 25/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 3.7x (a 83% discount to the sector median of 22.3x), P/B of 0.6x, P/S of 64.1x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Returns on equity of 17.0% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
A conservative balance sheet (9% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Positive momentum (73th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
Return on assets of 15.6% indicates efficient deployment of the full asset base, not just equity capital.
The Reduce rating (composite 45.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -1% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
We assign a Medium uncertainty rating to ORAMED PHARMACEUTICALS INC.. The stock presents a balanced risk profile: current negative profitability (net margin -382.1%). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -382.1%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 74th percentile and quality factor at the 35th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (9% D/E) limits balance sheet risk; above-average stability (74th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate ORAMED PHARMACEUTICALS INC.'s capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 17.0%, and the balance sheet is managed within acceptable parameters (D/E: 9%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; ORAMED PHARMACEUTICALS INC. falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, ORAMED PHARMACEUTICALS INC. receives a Reduce rating with a composite score of 45.6/100 (rank #2708 of 7,333). Our quantitative framework assigns a No Moat (25/100, trend: stable), Medium uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 47/100.
Our analysis does not support a constructive view on ORAMED PHARMACEUTICALS INC. at this time. The combination of limited competitive advantages, medium uncertainty, and standard capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign ORAMED PHARMACEUTICALS INC. a meaningful economic moat, scoring 25/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, economic value creation, reached only 11.2/20.
The strongest moat sources are economic value creation (11.2/20) and financial resilience (8.4/20). ROE proxy 17.0% (sector -2.5%). Interest coverage N/A. These pillars form the core of ORAMED PHARMACEUTICALS INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and margin superiority (1/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ORAMED PHARMACEUTICALS INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-1%) that pressure the earnings outlook, returns on equity of 17.0% driving shareholder value creation. The margin cascade from 1% gross to -225% operating to -382.1% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 35th percentile.
The margin profile shows gross margins of 1%, operating margins of -225%, net margins of -382.1%. Return metrics include ROE of 17.0% and ROA of 15.6%. Relative to the Manufacturing sector, gross margins are 41.9 percentage points below the sector median of 43%, and ROE of 17.0% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 9%, revenue growth of -1%. The sector median D/E is 0%, putting ORAMED PHARMACEUTICALS INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Thin net margins of -382.1% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Above 50MA
37.18%
Net New Highs
+51081
Oramed (ORMP) gets $18M from Scilex, lifting total returns to $118M, and declares a $0.25/share dividend for Jan 2026—read the key details now.
Oramed Pharmaceuticals announced a Rights Plan to protect against hostile takeovers, distributing one common stock purchase right per outstanding share, with rights becoming exercisable if a person/group acquires 15% or more of outstanding stock.
Gainers Kidpik Corp. (NASDAQ: PIK) shares jumped 122% to $1.29. Kidpik teamed up with Disney to celebrate the release of Disney+ original movie 'World's Best'. Conformis, Inc. (NASDAQ: CFMS) shares rose 91.3% to $0.2969 after the company agreed to be acquired by restor3d, a leading personalized 3D-printed orthopedic company, for a purchase price of $2.27 per share in cash. SCWorx Corp. (NASDAQ: WORX) gained 62% to $0.5800. OncoSec Medical Incorporated (NASDAQ: ONCS) shares jumped 41.3% to $0.2969 after gaining around 8% on Thursday. Surgalign Holdings, Inc. (NASDAQ: SRGA) shares gained 40.9% to $0.2839. Surgalign received NASDAQ delisting notice following Chapter 11 filing. Nuvve Holding Corp. (NASDAQ: NVVE) shares rose 34% to $0.6101 after the company launched Astrea AI forecasting for Nordic Energy market. Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 24.7% to $0.2749. Smith & Wesson Brands, Inc. (NASDAQ: SWBI) shares climbed 17% to $13.15 as the company reported better-than-expected results for its fourth quarter and raised its quarterly dividend from $0.10 to $0.12 per share. Applied Digital Corporation (NASDAQ: APLD) rose 15.8% to $11.20 after the company announced its AI cloud service has secured a second AI customer with an agreement worth up to $460 million over 36 months. Leafly Holdings, Inc. (NASDAQ: LFLY) gained 13.2% to $0.32. Appreciate Holdings, Inc. (NASDAQ: SFR) jumped 11.7% to $0.38. Trupanion, Inc. (NASDAQ: TRUP) gained 10.4% to $22.71 after California and New York approved the company's requested rate increases. CarMax, Inc. (NYSE: KMX) jumped 10% to $86.14 after the company reported better-than-expected first-quarter EPS and sales results. TRxADE HEALTH, Inc. (NASDAQ:
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 1847 Holdings LLC (NASDAQ: EFSH) gained 64.5% to $0.9050 after the company reported a 27.6% increase in revenue to $15.4 million and achieved profitability for the first quarter. Harbor Custom Development, Inc. (NASDAQ: HCDI) surged 49.5% to $8.97 following first-quarter results. WiSA Technologies, Inc. (NASDAQ: WISA) rose 47.4% to $2.33 after the company signed a Letter of Intent to acquire Comhear. WiSA expects acquisition to be accretive beginning in the fourth quarter and sees FY24 revenue of $10 million to $15 million. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) gained 39% to $3.94 as the company said that its Chinese partner, HTIT, has successfully completed a Phase 3 oral insulin clinical trial and submitted a marketing authorization application in China. LM Funding America, Inc. (NASDAQ: LMFA) jumped 34% to $0.9816 following better-than-expected results for the first quarter. MGO Global, Inc. (NASDAQ: MGOL) shares gained 33.2% to $1.5910. MGO Global is scheduled to host a webcast on May 16, 2023 to discuss recent operational developments and financial results for the first quarter. Xenetic Biosciences, Inc. (NASDAQ: XBIO) jumped 24.8% to $4.12. Xenetic Biosciences recently announced a 1-for-10 reverse stock split. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) gained 24% to $148.99 after the company announced the FDA voted in favor of its gene therapy to treat Duchenne muscular dystrophy late Friday. Multiple analysts raised price targets following the announcement. Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) surged 22% to $2.50. ZK International Group Co., Ltd. (NASDAQ: ZKIN) gained 21.7% to $0.7790. Peraso Inc. (NASDAQ: PRSO) shares climbed 18.1% to $0.4263. Peraso is expected to release its first-quarter financial results on May 15, 2023 after the closing bell. InspireMD, Inc. (NASDAQ: NSPR) jumped 18% to $1.71 as the company announced a ...
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. PepGen Inc. (NASDAQ: PEPG) On Jan. 8, PepGen said First Patient was dosed in CONNECT1-EDO51 Phase 2 clinical trial of PGN-EDO51 for duchenne muscular dystrophy patients amenable to Exon 51 skipping. The company’s stock ...